Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Frisbie

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2025
Understanding CXCR2 antagonism with a dynamic allosteric ternary complex modelRui Li, Richard Frisbie, Fabien Vincent, et al.
European Journal of Medicinal Chemistry|January 20, 2018
Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitorsFrank Lovering, Paul Morgan, Christophe Allais, et al.
Journal of Medicinal Chemistry|August 5, 2016
Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic NephropathyKimberly O Cameron, Daniel W Kung, Amit S Kalgutkar, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2025
Understanding CXCR2 antagonism with a dynamic allosteric ternary complex modelRui Li, Richard Frisbie, Fabien Vincent, et al.
European Journal of Medicinal Chemistry|January 20, 2018
Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitorsFrank Lovering, Paul Morgan, Christophe Allais, et al.
Journal of Medicinal Chemistry|August 5, 2016
Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic NephropathyKimberly O Cameron, Daniel W Kung, Amit S Kalgutkar, et al.
Pageof 1